Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesPRNewsWire · Oct 7, 2026
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial ProgramBenzinga · Sep 23, 2026
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentPRNewsWire · Sep 23, 2026
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesPRNewsWire · Sep 21, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02PRNewsWire · Sep 14, 2026
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 10, 2026Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.45 | -$0.27 | Beat |
| May 13, 2026 | -$0.38 | -$3.16 | Miss |
| Mar 25, 2026 | -$0.19 | -$3.42 | Miss |
| Nov 12, 2025 | -$0.42 | -$0.74 | Miss |
| Aug 12, 2025 | -$0.39 | -$0.45 | Miss |
| May 14, 2025 | -$0.38 | -$0.20 | Beat |